Abstract
In this chapter we review the interactions of oxidative and nitrosative stress (O&NS), immune-inflammation, tryptophan catabolites (TRYCATs) and suboptimal mitochondrial functioning in driving changes in the melatonergic pathways in major depressive disorder (MDD). We propose that such interactive biological processes provide a framework for the development of a number of novel pharmaceutical and nutriceutical treatment targets, with relevance to a classification of MDD that is based on biological underpinnings rather than on subjective phenomenology.
Keywords: Inflammation, Major depressive disorder, Mitochondria, Nitrosative stress, Oxidative stress, Tryptophan catabolites.
Related Journals
Current Drug Safety
Inflammation & Allergy - Drug Targets (Discontinued)
Recent Patents on Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Current Drug Targets - Inflammation & Allergy
Current Bioactive Compounds
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Anti-Cancer Agents in Medicinal Chemistry
Current Drug Targets
Letters in Drug Design & Discovery
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Advances in Cancer Drug Targets
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development